Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up
Executive Summary
The latest drug development news and US FDA highlights from our Performance Tracker.
You may also be interested in...
Spring Awakening: NDA Submissions To Watch For
If companies meet their publicly stated NDA filing targets, at least four breakthrough-designated therapies will arrive at US FDA in March.
Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: A Little Bit Of (Nearly) Everything
The latest drug development news and highlights from our US FDA Performance Tracker.